These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34049452)

  • 1. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.
    Spindle TR; Martin EL; Grabenauer M; Woodward T; Milburn MA; Vandrey R
    J Psychopharmacol; 2021 Jul; 35(7):786-803. PubMed ID: 34049452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
    Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial.
    Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
    JAMA Netw Open; 2018 Nov; 1(7):e184841. PubMed ID: 30646391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
    Sholler DJ; Zamarripa CA; Spindle TR; Martin EL; Kuntz D; Vandrey R; Grabenauer M
    J Anal Toxicol; 2022 Oct; 46(8):882-890. PubMed ID: 35770374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
    Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
    J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of oral and vaporized cannabis alone, and in combination with alcohol, on driving performance using the STISIM driving simulator: A two-part, double-blind, double-dummy, placebo-controlled, randomized crossover clinical laboratory protocol.
    Zamarripa CA; Novak MD; Weerts EM; Vandrey R; Spindle TR
    Front Pharmacol; 2022; 13():964749. PubMed ID: 36147331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.
    Spindle TR; Zamarripa CA; Russo E; Pollak L; Bigelow G; Ward AM; Tompson B; Sempio C; Shokati T; Klawitter J; Christians U; Vandrey R
    Drug Alcohol Depend; 2024 Apr; 257():111267. PubMed ID: 38498958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults.
    Sholler DJ; Strickland JC; Spindle TR; Weerts EM; Vandrey R
    Addict Biol; 2021 Jul; 26(4):e12968. PubMed ID: 32985064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid.
    Bosker WM; Theunissen EL; Conen S; Kuypers KP; Jeffery WK; Walls HC; Kauert GF; Toennes SW; Moeller MR; Ramaekers JG
    Psychopharmacology (Berl); 2012 Oct; 223(4):439-46. PubMed ID: 22581391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration.
    Newmeyer MN; Swortwood MJ; Taylor ME; Abulseoud OA; Woodward TH; Huestis MA
    J Appl Toxicol; 2017 Aug; 37(8):922-932. PubMed ID: 28138971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis effects on driving lateral control with and without alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
    Drug Alcohol Depend; 2015 Sep; 154():25-37. PubMed ID: 26144593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):690-701. PubMed ID: 26257143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial.
    Marcotte TD; Umlauf A; Grelotti DJ; Sones EG; Mastropietro KF; Suhandynata RT; Huestis MA; Grant I; Fitzgerald RL
    JAMA Psychiatry; 2023 Sep; 80(9):914-923. PubMed ID: 37531115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.
    Suraev A; McCartney D; Marshall NS; Irwin C; Vandrey R; Grunstein RR; D'Rozario AL; Gordon C; Bartlett D; Hoyos CM; McGregor IS
    Psychopharmacology (Berl); 2024 Sep; 241(9):1815-1825. PubMed ID: 38758300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ
    Boggs DL; Cortes-Briones JA; Surti T; Luddy C; Ranganathan M; Cahill JD; Sewell AR; D'Souza DC; Skosnik PD
    J Psychopharmacol; 2018 Dec; 32(12):1308-1318. PubMed ID: 30255720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a phone-based measure of impairment after acute oral ∆
    Pabon E; de Wit H
    J Psychopharmacol; 2019 Sep; 33(9):1160-1169. PubMed ID: 31407943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.